What is Axsome?
Axsome Therapeutics, Inc. operates at the intersection of neuroscience and advanced pharmacology, focusing on the development of innovative therapies for central nervous system conditions. The company distinguishes itself through a commitment to novel mechanisms of action, aiming to provide physicians and patients with meaningful alternatives where traditional treatment options have historically fallen short. By prioritizing high-unmet-need indications, Axsome has established a robust market position, effectively bridging the gap between early-stage clinical research and commercial-scale therapeutic delivery. Their portfolio is characterized by a rigorous focus on improving patient outcomes through scientific precision and strategic asset management.
How much funding has Axsome raised?
Axsome has raised a total of $650.5M across 7 funding rounds:
Debt
$3.7M
Debt
$2M
Debt
$1.3M
Debt
$2.5M
Stock Offering
$51M
Debt
$20M
Debt
$570M
Debt (2013): $3.7M, investors not publicly disclosed
Debt (2014): $2M, investors not publicly disclosed
Debt (2014): $1.3M, investors not publicly disclosed
Debt (2015): $2.5M, investors not publicly disclosed
Stock Issuance/Offering (2015): $51M, investors not publicly disclosed
Debt (2016): $20M with participation from Silicon Valley Bank
Debt (2025): $570M led by Blackstone
Key Investors in Axsome
Blackstone
Blackstone is a global investment firm that focuses on building and managing diversified asset portfolios across private equity, real estate, credit and strategic alternatives.
Silicon Valley Bank
SVB Financial Group offers commercial and private banking, asset management, private wealth management, brokerage and investment services, funds management, and business valuation services.
Undisclosed Investors
What's next for Axsome?
With the successful closure of this major strategic investment, Axsome is well-positioned to accelerate its clinical development programs and expand its commercial footprint. The infusion of capital provides the necessary runway to advance late-stage pipeline candidates, potentially transforming the standard of care for complex CNS conditions. Moving forward, the company is expected to focus on operational scaling and the potential expansion of its therapeutic reach, leveraging its strengthened balance sheet to navigate the complexities of the biopharmaceutical market. Investors and industry analysts will likely monitor the company's progress in translating this financial momentum into tangible clinical milestones and long-term value creation.
See full Axsome company page
